Rising Incidence of Diabetes in Children Amidst COVID-19: A Comprehensive Analysis

By HEOR Staff Writer

July 28, 2023

The COVID-19 pandemic has had far-reaching implications, with recent reports indicating a surge in the incidence of pediatric diabetes. To gain a clearer understanding of this association, a systematic review and meta-analysis of various studies published in English was conducted. 

The analysis included 42 studies, covering 102,984 incident diabetes cases. The results revealed a significant increase in the incidence rate of type 1 diabetes and diabetic ketoacidosis (DKA) in children and adolescents during the first two years of the pandemic compared to the pre-pandemic period. 

While the exact mechanism linking COVID-19 to the onset of diabetes remains unclear, potential factors might include lifestyle changes, stress, social isolation, and disruptions in healthcare access due to pandemic containment measures. 

These findings underscore the urgent need for increased resources and support for the growing number of children and adolescents with diabetes.  Future studies are required to determine whether this trend continues, and to shed light on the possible underlying mechanisms explaining these temporal changes. 

 

The increased incidence of DKA at diagnosis highlights the need to identify gaps in the pathway from the onset of diabetes symptoms to diagnosis. This information is crucial for developing effective strategies to prevent DKA at diagnosis in children. 

 

 

Reference url

Recent Posts

Economic Impact of Fragmented Care: Tackling Obesity, Diabetes, and Cardiovascular Disease in Europe

By João L. Carapinha

April 23, 2026

Europe loses approximately €240 billion every year because of the interconnected burdens of obesity diabetes cardiovascular disease (EFPIA Guest Blog). Fragmented healthcare systems that treat late-stage complications instead of preventing disease progression are largely responsible for this mass...
Advancements in HIV Two-Drug Regimen: FDA Approves IDVYNSO for Virologically Suppressed Patients
The FDA has approved Merck’s HIV two-drug regimen, IDVYNSO™ (doravirine/islatravir), the first and only non-integrase strand transfer inhibitor (non-INSTI), tenofovir-free, once-daily complete regimen for adults with virologically suppressed HIV-1 infection. First Non-INSTI, Tenofovi...
Progress and Challenges in the FDA Accelerated Approval Pathway: A Policy Roadmap for HEOR

By HEOR Staff Writer

April 21, 2026

In this update, we analyze the evolution of the FDA Accelerated Approval Pathway since the 2022 Food and Drug Omnibus Reform Act (FDORA), highlighting measurable improvements, ongoing evidentiary gaps, and policy recommendations critical for health economics and outcomes research (HEOR), pricing,...